01176ojm 2200277z- 450 991015772050332120230913112557.01-933311-13-4(CKB)3710000001002247(BIP)052337505(EXLCZ)99371000000100224720231107c2007uuuu -u- -engChristmas Carol, AFreshwater SeasThis presentation of the beloved tale tells the classic story of the long night Ebenezer Scrooge spent with the ghosts of Christmas, the lessons it taught him, the change it made in his life, and the joy it brought to him and all who knew him. It tells the story the way Dickens wrote it, including scenes and descriptions other versions skip over.On this recording, the story is not merely read, it comes to life with voices and musicFictionLiterature And Fiction (General)Dickens Charles154882Bethune Robert1954-cmpnrtBerneis SusienrtUnderwood TomnrtAUDIO9910157720503321Christmas Carol, A3599857UNINA04545nam 2201021z- 450 991058593580332120220812(CKB)5600000000483127(oapen)https://directory.doabooks.org/handle/20.500.12854/91177(oapen)doab91177(EXLCZ)99560000000048312720202208d2022 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierRisk Prediction and New Prophylaxis Strategies for Thromboembolism in CancerBaselMDPI - Multidisciplinary Digital Publishing Institute20221 online resource (202 p.)3-0365-4707-X 3-0365-4708-8 Thromboembolism is a compelling challenge in cancer care because of its life-threatening nature as well as its impact on specific treatments. Current guidelines do not generally recommend antithrombotic prophylaxis, except in selected categories of patients at high risk of thrombosis. Accordingly, several clinical decision models have been developed to guide the oncologist in thromboembolic risk assessment and targeted prophylaxis. Low-molecular-weight heparins (LMWH) are currently considered as the standard approach in clinical practice guidelines, but recent randomized controlled trials (RCT) indicate that direct oral anticoagulants (DOACs) are effective for the treatment/prophylaxis of cancer-associated thromboembolism. However, many unanswered questions remain on the efficacy and safety of anticoagulants in selected cancer subgroups, and in primary and secondary prevention settings, where anticoagulation needs to be balanced on the risk of bleeding complications. Presently, patient selection remains the main challenge. Improvement in existing VTE risk models or the construction of alternative risk assessment tools are needed in order to ameliorate the risk stratification of cancer patients. This reprint will cover the current clinical evidence supporting the standard of care and emerging treatment/prophylactic options for cancer-associated thromboembolism during both active treatment and simultaneous/palliative care. Tailored approaches based on the use of individualized factors to stratify the thrombotic/bleeding risk in each individual patient are discussed.Medicine and NursingbicsscOncologybicsscALKanticoagulantsarterial thrombosiscancercancer associated thrombosiscancer-associated venous thromboembolismchemotherapycoagulation activationcoumarinsdeep vein thrombosisdirect oral anticoagulantdirect oral anticoagulantsDOACDOACsendogenous heparinheparan sulfateheparanaseHodgkin lymphomahospiceintegrated careKRASlocally advanced breast cancerlow molecular weight heparinlow molecular weight heparinslow-molecular weight heparinlow-molecular-weight heparin (LMWH)lymphomamalignancymolecular subtypemultiple myeloman/aneoplasmsNon-Hodgkin lymphomapalliative care unitspancreatic cancerpCRprognostic modelprophylaxispulmonary embolismrisk assessment modelsrisk factorsROS1simultaneous caresurvivalthromboprophylaxisthrombosistreatmentUFHvenous thromboembolismVKAVTEMedicine and NursingOncologyFerroni Patriziaedt1280411Roselli MarioedtGuadagni FiorellaedtFerroni PatriziaothRoselli MarioothGuadagni FiorellaothBOOK9910585935803321Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer3016900UNINA